Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

Reno, Nevada ( -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the commercial availability of Karl Storz’s New Blue Light equipment powered by Saphira™ in the U.S.

As part of the rollout, Karl Storz plans to host a Virtual Launch event for the medical community streamed from its El Segundo, California office where Sia Daneshmand M.D. and Kristin Scarpato M.D. M.P.H. will discuss the clinical benefits of using blue light cystoscopy (BLC®) with Cysview® for NBMIC*,

while sharing their perspectives on the advantages that the New Blue Light system provides over the original system for TURBT**. The Virtual Launch event is scheduled to take place on October 13, 2022 at 4:00pm Pacific Time.

We are pleased to share that Karl Storz has begun filling Obsolescence Protection Program (OPP) orders for customers who purchased New Blue Light system upgrades last year,” said Geoff Coy, Vice President and General Manager, North America. “Orders for the new Saphira system appear to be outpacing orders from the past signaling pent up demand for the advanced technology, and we expect to begin filling new account orders in the fourth quarter. Given the strong demand, we continue to believe that BLC is on its way to becoming the standard of care for endoscopic visualization of bladder cancer.”

“Uro-oncologists and their staff have expressed a strong desire to have the New Blue Light system at their hospitals, and the upcoming Virtual Launch Event is an opportunity to showcase the system’s benefits and broaden awareness of BLC in the market,” said Ken Pugh, Head of North America Marketing and Alliance Management. “Accordingly, we are working diligently with our partners to ensure that all customers who want the New Blue Light, have it for all appropriate patients with NMIBC.”

Dr. Sia Daneshmand, M.D., is Professor of Urology with a Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director at the University of Southern California (USC) in Los Angeles.

Dr. Kristin Scarpato, M.D., M.P.H., is Associate Professor Department of Urology residency program director and vice chair of education for the Department of Urology, Division of Urologic Oncology at Vanderbilt University Medical Center in Tennessee.

*NMIBC: Non‐muscle invasive bladder cancer

**TURBT: Transurethral resection of bladder tumor

Note to editors:
Hexvix®/Cysview® and BLC® are registered trademarks of Photocure ASA. IMAGE1 S™ and Saphira™ are registered trademarks of KARL STORZ Endoscopy.

This press release may contain product details and information which are not valid, or a product that is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin.

1 Globocan. a) 5-year prevalence / b) incidence/mortality by population.  Available at:, accessed [January 2022]
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol 2009;27:295–300
4 Bladder Cancer. American Cancer Society.

Source: "Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S. ". 2022. Photocure.Com.
email news signup